🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Regeneron Pharmaceuticals, Inc. REGN NDXSPX

Healthcare · Biotechnology · United States
https://www.regeneron.com
Company Profile ↓
$664.45
+17.09% 1Y
Mkt Cap$68.45B
P/E16.23
P/B2.15
Div. Yield0.57%
52W High$810.08
52W Low$539.56
Book Value$308.32
EPS (TTM)$40.94

Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 16.3% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 29.2% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 16.2, below the sector median of 25.9.

Healthy Margins

Maintains a net profit margin of 29.6%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.09.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $14.34B (+1.0% YoY); net profit $4.50B.
  • Trailing 12 Months Year-on-year growth — revenue +19.0%, earnings -7.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 29.2%, profit CAGR 16.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:29.18%
1 Year:19.00%

Compounded Profit Growth

5 Years:16.32%
1 Year:-7.20%

Stock Price Performance

1 Year:+17.09%
6 Months:-13.25%
3 Months:-11.92%
1 Month:+8.55%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 46% of range
$539.56 $810.08
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)58.33 · Neutral
Price Performance
1M+8.55%
3M-11.92%
6M-13.25%
1Y+17.09%
Valuation vs Sector

P/E of 16.23 is below the sector median of 25.88 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Excellent profit margin of 29.6%.
  • Compounding revenue at 29.2% over 5 years.
  • Profit CAGR of 16.3% over 5 years.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
16.23
Industry PE
25.88
Forward P/E
12.18
PEG Ratio
1.15
Book Value
$308.32
Price to Book
2.15
P/S
4.67
EV/EBITDA
13.85
Dividend Yield
0.57%

Growth (CAGR)

Revenue 5Y
29.18%
Profit 5Y
16.32%
Revenue (YoY)
19.00%
Earnings (YoY)
-7.20%

Profitability & Returns

ROCE
10.23%
ROE
14.55%
ROA
6.13%
Profit Margin
29.65%
Op Margin
20.66%
Gross Margin
43.89%
EPS (Latest Qtr)
$6.75
EPS (TTM)
$40.94

Balance Sheet & Liquidity

Debt/Equity
0.09
Quick Ratio
2.84
Current Ratio
3.56
Debt
$2.71B
Total Assets
$40.87B
Current Assets
$18.21B
Working Capital
$13.65B

Ownership

Promoter Holding
2.03%
Chg in Prom Hold
-0.00%
FII / Inst Holding
92.24%
Chg in FII Hold
0.02%

Financial Snapshot

Enterprise Value
$68.45B
Total Revenue (TTM)
$14.92B
EBITDA
$4.38B
Free Cash Flow
$3.27B
Operating Cash Flow
$5.01B
Shares Outstanding
103.02M
Gross Margin
43.89%
Payout Ratio
8.74%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 REGN Regeneron Pharmaceuticals, Inc. NDXSPX 664.45 16.23 $68.45B 0.57% 10.23% 14.55% 29.18% 16.32%
2 LLY Eli Lilly and Company SPX 1,156.63 41.13 $1.03T 0.60% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 247.02 28.66 $594.63B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.11 119.08 $431.29B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 418.52 31.54 $380.08B 2.18% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 123.61 34.82 $305.29B 2.82% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 168.37 26.10 $261.12B 1.87% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 535.29 29.40 $198.93B 0.35% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 358.32 24.92 $193.39B 2.80% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ------1.32B1.47B1.50B1.58B1.51B1.61B1.66B1.93B1.37B1.58B1.74B1.86B1.83B1.95B2.29B2.42B2.53B5.14B3.45B2.97B2.86B2.94B3.16B3.16B3.36B3.15B3.55B--3.03B3.68B3.75B3.88B3.61B
Cost of Revenue -----------------------------------464.30M530.20M521.60M584.60M669.40M
Gross Profit -----------------------------------2.56B3.15B3.23B3.30B2.94B
Operating Expenses -----------------------------------1.97B2.07B2.12B2.40B2.19B
Operating Income 392.42M-329.31M291.63M362.80M-430.54M550.31M559.93M-567.20M622.20M626.90M-480.00M315.60M738.50M-700.10M656.40M1.05B-1.11B3.35B1.85B1.26B1.11B1.22B946.70M1.02B1.11B751.40M1.07B--591.70M1.08B1.11B898.60M744.80M
EBITDA -----------------------------------1.04B1.66B1.92B1.20B967.30M
Interest Expense -----------------------------------8.70M3.60M19.30M12.20M12.90M
Pretax Income -----------------------------------905.00M1.52B1.76B1.04B831.20M
Tax Provision -----------------------------------96.30M127.10M303.30M199.10M104.00M
Net Income 210.40M154.99M181.38M196.22M264.80M253.12M248.90M387.70M388.30M173.50M478.00M551.40M594.70M820.40M461.10M193.10M669.60M792.00M624.60M897.30M842.10M1.15B1.12B3.10B1.63B973.50M852.10M1.32B817.80M968.40M1.01B722.00M1.43B--808.70M1.39B1.46B844.60M727.20M
Diluted EPS 1.821.341.591.692.272.192.163.343.321.504.164.825.177.153.991.685.866.935.437.617.3910.2410.0927.9714.338.617.4711.667.178.508.896.2712.41--7.2712.8113.627.866.75
R&D Expense 425.92M-470.11M559.93M543.05M-507.44M509.98M529.75M-498.60M529.30M557.00M-486.10M885.50M526.00M-583.90M722.00M684.60M-742.90M714.20M665.40M843.80M794.30M911.30M1.10B1.09B1.08B1.25B1.20B1.27B-1.33B1.42B1.48B-1.54B

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 238.46M379.27M459.07M445.82M1.38B2.10B2.82B4.10B4.86B5.87B5.15B6.56B8.50B-12.17B13.12B14.20B14.34B
Cost of Revenue --------------1.56B1.82B1.97B2.10B
Gross Profit --------------10.61B11.30B12.23B12.24B
Operating Expenses --------------5.87B7.25B8.24B8.54B
Operating Income -86.25M-74.10M-97.47M-205.16M457.71M743.05M823.92M1.25B1.33B2.08B2.53B2.21B3.58B-4.74B4.05B3.99B3.70B
EBITDA --------------5.26B4.69B5.32B5.82B
Interest Expense --------------59.40M73.00M55.20M43.80M
Pretax Income --------------4.86B4.20B4.78B5.23B
Tax Provision --------------520.40M245.70M367.30M725.80M
Net Income -79.13M-67.83M-104.47M-221.76M750.27M413.74M338.13M636.06M895.50M1.20B2.44B2.12B3.51B-4.34B3.95B4.41B4.50B
Diluted EPS ---1.26-2.456.753.722.985.527.7010.3421.2918.4630.52-38.2234.7738.3441.48
R&D Expense 274.90M398.76M489.25M529.51M625.55M859.95M1.27B1.62B2.05B2.08B1.47B2.45B2.65B2.86B3.59B4.44B5.13B5.85B

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --741.20M1.09B1.32B2.08B2.95B3.84B5.61B6.97B8.76B11.73B14.81B17.16B-29.21B33.08B37.76B40.56B
Current Assets ---------------15.88B19.48B18.66B18.02B
Cash & Equivalents 498.93M247.80M207.07M112.57M483.61M230.28M535.61M648.72M809.10M535.20M812.70M1.47B1.62B2.19B-3.11B2.73B2.49B3.12B
Inventory ---------------2.40B2.58B3.09B3.20B
Receivables ---------------5.33B5.67B6.21B5.74B
Total Liabilities --344.44M561.62M837.85M835.11M998.94M1.29B1.95B2.52B2.62B2.98B3.72B6.14B-6.55B7.11B8.41B9.30B
Current Liabilities --93.58M109.06M148.27M163.55M298.83M654.66M811.16M1.24B1.14B1.44B2.10B2.70B-3.14B3.42B3.94B4.37B
Long Term Debt ------------01.98B-1.98B1.98B1.98B1.99B
Total Debt ---------------2.70B2.70B2.70B2.71B
Total Equity 459.35M421.51M396.76M527.82M485.73M1.26B1.96B2.55B3.65B4.45B6.14B8.76B11.09B11.03B-22.66B25.97B29.35B31.26B
Shares Outstanding ---------------132.20M134.92M137.82M139.42M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -89.09M-69.94M99.22M-141.68M-74.61M588.60M752.43M1.33B1.49B1.31B2.20B2.43B2.62B-5.01B4.59B4.42B4.98B
Investing Cash Flow 30.82M-2.15M-437.03M128.47M-81.07M-355.45M-420.78M-907.60M-1.05B-1.01B-1.46B-2.03B-70.60M--3.78B-3.19B-2.47B-629.10M
Financing Cash Flow -192.86M31.36M243.31M384.25M-97.65M72.19M-218.55M-262.80M-700.50M-24.40M-77.10M-252.10M-1.97B--1.01B-1.79B-2.20B-3.72B
Capital Expenditure ---------------1.62B-926.40M-881.60M-1.21B
Free Cash Flow --------------3.40B3.67B3.54B3.77B
Net Change in Cash --------------221.30M-381.20M-248.10M634.40M
Share Buybacks --------004.40M275.90M5.85B1.65B2.08B2.23B2.60B3.44B
Dividends Paid ---------------00370.30M

Ratios (Annual)

Figures in %.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------------87.2%86.2%86.1%85.4%
Operating Margin % -36.2%-19.5%-21.2%-46.0%33.2%35.3%29.2%30.5%27.4%35.4%49.3%33.7%42.1%-38.9%30.9%28.1%25.8%
Net Margin % -33.2%-17.9%-22.8%-49.7%54.4%19.7%12.0%15.5%18.4%20.4%47.5%32.3%41.3%-35.6%30.1%31.1%31.4%
ROE % -18.8%-17.1%-19.8%-45.7%59.7%21.1%13.3%17.4%20.1%19.5%27.9%19.1%31.9%-19.1%15.2%15.0%14.4%
ROCE % --11.4%-9.9%-17.5%23.9%28.0%25.9%26.1%23.2%27.3%24.6%17.4%24.7%-18.2%13.6%11.8%10.2%

Shareholding Pattern

Insiders
2.03%
Institutions
92.24%
Public Float
94.15%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.69% 8.95M $5.94B
2 Vanguard Capital Management LLC 6.46% 6.65M $4.42B
3 State Street Corporation 4.53% 4.66M $3.10B
4 Dodge & Cox Inc. 4.33% 4.46M $2.96B
5 JPMORGAN CHASE & CO 4.19% 4.31M $2.86B
6 Franklin Resources, Inc. 2.64% 2.72M $1.81B
7 Geode Capital Management, LLC 2.53% 2.61M $1.73B
8 Price (T.Rowe) Associates Inc 2.11% 2.18M $1.45B
9 Nuveen, LLC 2.00% 2.07M $1.37B
10 LOOMIS SAYLES & CO L P 1.86% 1.91M $1.27B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for REGN

Google News Wed, 15 Jul 2026

Regeneron Pharmaceuticals (REGN) Stumbled In A Trial Setback, Is The Stock Still Cheap? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxNZEl5YVBaaEZuRlJxWG1rN0tYMVlWTkNhODNEMUp0UDJhTUV3NE9BVDF0MHdGQzhtOXJjZjZINlpBX1oyRnJZQk1neWU5cC1yNkJJSE5rb2dtTU41NF9nRVh0MHJ4TFpsSGJxU3NtNDNOS3ZVS09yRk1VaDluZzFEOGxLazNvdmk1dXlmMj…

Google News Sun, 28 Jun 2026

Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPcEFMLXh0SlZzWkdHV1RaM3I5b2kxeF9Ub3k5XzNKSm1sd2JzaHhxemtmSFNucmkta2hfYVVzXzZxSGUtWkpJYUZmZHpTNWRqTzJHWE45dkpHZDk2N3lMcjlzcTdmZ0VmX0Q5Z3dSUlBmVlNrMmU1Y2MyamhUTkNCQjZPUHQwWWgxNGppcW…

Google News ue, 14 Jul 2026

1 Large-Cap Stock with Exciting Potential and 2 We Turn Down - StockStory

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQWXBrMVpFSnJBbWc2cGNja1M5dTl5MTd0a1JNT0RfRXAyOUNZaHFlRmloWVdfT21Yc1BYU0hQc1ZDX1dqbTdhSEx2bGhWUE53d09JSHZ2eVR3QWJGdXREN2FJcTQzaDZDUzN4Vzd3QTAwaFBlSHEwNjZrQTYyX2k3ZjRuWUhRQzBDNzEtZm…

Google News Wed, 15 Jul 2026

Regeneron (REGN) Receives FDA Orphan Drug Designation for Dupilu - GuruFocus

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQY3IwRDM1SGNON0J2T1R2aWRwLTFIV2h6QUt1R2ppbVA3Z1h5dXNuYWZxeHJ0dmJ0THBoVFJoVG1XTW5VNmRYSjAzcXlPVjdIMnA3dkt6ZVU2a3pvUGdyQmtwLWJKRUN5OWdEUVoyNGU4MndFMHdhUUE2RFVmZkFtMEpJdFlrdXlsSWkzVX…

Google News ue, 14 Jul 2026

Nasdaq, S&P 500 Futures Retreat After Record Week: Why NVDA, NOW, POET, IBRX, UNH, REGN Are In Focus - Stocktwits

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxQckpYdk1taWRmU1ZLdGRTcE5IZ2R6dUpBMmVuRzJyanFZNUNMaGR2bHEyci1LbjN1WElRakdrYl9OWHpYUmt1U0cxNEZkUGdmYktEdkFEcWtkS0ZLQkdMUkZPbmNPaHVfbk9KUUlXVC1HN3M3MmZXU3NtZEtjVENvZFdHRDNWdnFBcDA0WW…

Google News ue, 14 Jul 2026

REGN 260717 875.00C (REGN260717C875000) Stock Options Chain | Quotes & News - Moomoo

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTFB0MFBuQnNSTW9PbExSMGpmc1ZycnhwWXI0cF9SRDU1N0NWc1NlUGdyUWtkSEwtSWVnd0k5S0VoVXJMa0RFakk1bXJxa1NtZWdVMUUzNEdRSHZSNExhbndyNg?oc=5" target="_blank">REGN 260717 875.00C (REGN260717C87500…

REGN — Frequently Asked Questions

What is the current share price of Regeneron Pharmaceuticals, Inc. (REGN)?

As of 2026-07-15 16:51 PDT, Regeneron Pharmaceuticals, Inc. (REGN) trades at $664.45 on NasdaqGS. Its 52-week range is $539.56 to $810.08.

What is the market capitalisation of REGN?

Regeneron Pharmaceuticals, Inc. (REGN) has a market capitalisation of $68.45B on NasdaqGS.

What is the P/E ratio of REGN?

REGN trades at a trailing price-to-earnings (P/E) ratio of 16.23. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 2.15.

Does REGN pay a dividend?

Regeneron Pharmaceuticals, Inc. (REGN) currently offers a dividend yield of 0.57%.

What is the return on equity (ROE) of REGN?

REGN has a return on equity (ROE) of 14.55%. Its return on capital employed (ROCE) is 10.23%.

Is REGN a good stock to buy?

This page provides a data-driven analysis of Regeneron Pharmaceuticals, Inc. (REGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space